INVEX Therapeutics Ltd (IXC) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.171x

Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has a cash flow conversion efficiency ratio of -0.171x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-779.73K ≈ $-551.71K USD) by net assets (AU$4.55 Million ≈ $3.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is INVEX Therapeutics Ltd's balance sheet to measure how much of total assets are equity-financed.

INVEX Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)

This chart illustrates how INVEX Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check INVEX Therapeutics Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.

INVEX Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of INVEX Therapeutics Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Pila Pharma AB ST:PILA	-0.129x
Adroit Infotech Limited NSE:ADROITINFO	0.026x
PT Sunter Lakeside Hotel Tbk JK:SNLK	-0.018x
Flour Mills C. Sarantopoulos S.A. AT:KYSA	0.118x
Dynasty Gold Corp V:DYG	0.010x
Gratifii Ltd AU:GTI	0.129x
Warehouse REIT plc LSE:WHR	0.027x
Surya Biru Murni Acetylene Tbk PT JK:SBMA	0.022x

Annual Cash Flow Conversion Efficiency for INVEX Therapeutics Ltd (2019–2025)

The table below shows the annual cash flow conversion efficiency of INVEX Therapeutics Ltd from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see INVEX Therapeutics Ltd (IXC) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$5.25 Million ≈ $3.71 Million	AU$-652.57K ≈ $-461.74K	-0.124x	+71.05%
2024-06-30	AU$5.69 Million ≈ $4.02 Million	AU$-2.44 Million ≈ $-1.73 Million	-0.430x	-32.80%
2023-06-30	AU$21.23 Million ≈ $15.02 Million	AU$-6.87 Million ≈ $-4.86 Million	-0.324x	-172.89%
2022-06-30	AU$28.48 Million ≈ $20.15 Million	AU$-3.38 Million ≈ $-2.39 Million	-0.119x	-126.62%
2021-06-30	AU$32.08 Million ≈ $22.70 Million	AU$-1.68 Million ≈ $-1.19 Million	-0.052x	+20.38%
2020-06-30	AU$24.40 Million ≈ $17.27 Million	AU$-1.60 Million ≈ $-1.13 Million	-0.066x	-226.59%
2019-06-30	AU$11.44 Million ≈ $8.09 Million	AU$-230.13K ≈ $-162.83K	-0.020x	--

About INVEX Therapeutics Ltd

AU:IXC Australia Biotechnology

Market Cap

$5.85 Million

AU$8.27 Million AUD

Market Cap Rank

#28263 Global

#1469 in Australia

Share Price

AU$0.11

Change (1 day)

+0.00%

52-Week Range

AU$0.08 - AU$0.16

All Time High

AU$1.67